ATAI
Atai Beckley N.V
1W: -0.6%
1M: -19.0%
3M: -17.7%
YTD: -8.5%
1Y: +125.5%
3Y: +197.5%
$3.54
+0.16 (+4.73%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$3.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$667.7M
52W Range1.15-6.75
Volume3,200,716
Avg Volume4,602,074
Beta1.62
Dividend—
Analyst Ratings
Company Info
CEOSrinivas G. Rao
Employees54
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2021-06-18
Websiteataibeckley.com
Prof. J.H. Bavincklaan 7
Amstelveen 1183 AT
NL
Amstelveen 1183 AT
NL
31 20 793 2536
About Atai Beckley N.V
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
Latest News
AtaiBeckley sees promising mid-stage results for psychedelic antidepressant
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg
AtaiBeckley GAAP EPS of -$1.73
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Feilding-Mellen Cosm | A-Award | 10,000 | $4.48 | 2025-11-25 |
| Feilding-Mellen Cosm | D-Return | 40,400 | $4.48 | 2025-11-25 |
| HERSHBERG ROBERT | A-Award | 456,011 | $1.35 | 2025-11-05 |
| HERSHBERG ROBERT | A-Award | 103,000 | $4.48 | 2025-11-05 |
| HERSHBERG ROBERT | A-Award | 97,716 | $1.35 | 2025-11-05 |